CHMP recommendation spurs resistance-curbing anti-malarial to WHO markets
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion on Shin Poong Pharmaceutical's Pyramax, a new anti-malaria treatment for use outside the European Union, in a move intended to support countries outside the EU in getting new treatments which target World Health Organization diseases to the market.